Dear A-T Families,
Please find the following announcement about the NEAT Study, a follow-up clinical trial of EryDex, a low-dose steroid, to determine if it is safe and effective in people with A-T. For more information, you can reach out to the trial coordination team at neatcoordination@biotrial.com.
All the best,
Jennifer
Jennifer Thornton, Executive Director
Quince Therapeutics, a biotechnology firm based in San Francisco, is advancing a phase 3 clinical trial to evaluate EryDex, a potential new treatment for ataxia-telangiectasia (A-T). The NEAT study aims to understand the neurological effects of EryDex on individuals with A-T, focusing on its safety and how well it works.
The NEAT study is seeking to enroll 86 patients aged six to nine, and 20 patients aged ten years or older, over multiple sites in the US, the UK, and in Europe. Participants in the study will be randomly assigned to receive either EryDex or a placebo (a substance without any effect) for the duration of the six-month study. The treatment consists of six infusions, each scheduled about every 28 days. The effectiveness of the treatment will be measured by observing changes in a specific rating scale that assesses neurological function before and after the treatment.
After completing the trial, participants will have the opportunity to join a follow-up study – called open-label – that will continue to monitor and treat with EryDex. This offers all participants (even those who received the placebo during the entire trial) the opportunity to receive the drug after the initial study period.
Trial sites are expected to open in the upcoming weeks and months. If you or someone you know in the United States might be interested in participating in this study, please reach out to the trial coordination team at neatcoordination@biotrial.com. Be sure to mention the NEAT study in your email’s subject line. A team member will then get in touch with you to explain the next steps.
Quince Therapeutics hopes to potentially transform the treatment landscape for those affected by A-T. This is an opportunity for eligible participants to contribute to research that may lead to a new standard of care in A-T treatment. For more detailed information about the NEAT study and to see if you might be eligible to participate, visit Clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06193200.